アスペルギルス症治療薬市場:パイプラインレビュー(2019年下半期)

◆英語タイトル:Aspergillosis - Pipeline Review, H2 2019
◆商品コード:GDATA20MY0514
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2019年12月27日
◆ページ数:151
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥630,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Aspergillosis – Pipeline Review, H2 2019
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Aspergillosis – Pipeline Review, H2 2019, provides an overview of the Aspergillosis (Infectious Disease) pipeline landscape.

Aspergillosis is an infection or allergic response due to the Aspergillus fungus. Symptoms include cough, fever, headaches, general ill feeling (malaise), weight loss and chest pain. The predisposing factors include weakened immune system, low white blood cell level, asthma and long-term corticosteroid therapy. Treatment includes oral corticosteroids, antifungal and surgery.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Aspergillosis – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Aspergillosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Aspergillosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Aspergillosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 5, 3 and 19 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 3 molecules, respectively.

Aspergillosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Aspergillosis (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Aspergillosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Aspergillosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Aspergillosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Aspergillosis (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Aspergillosis (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Aspergillosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Aspergillosis – Overview
Aspergillosis – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Aspergillosis – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Aspergillosis – Companies Involved in Therapeutics Development
ABIONYX Pharma SA
Acea Biotech Inc
Amplyx Pharmaceuticals Inc
Argenx SE
Basilea Pharmaceutica Ltd
Bio-Synectics Inc
Biosergen AS
Cidara Therapeutics Inc
F2G Ltd
Galephar Pharmaceutical Research Inc
iCo Therapeutics Inc
Jiangsu Aosaikang Pharmaceutical Co Ltd
Matinas BioPharma Holdings Inc
Merck & Co Inc
Molecular Express Inc
Mycovia Pharmaceuticals Inc
Nanomerics Ltd
Novabiotics Ltd
Pulmatrix Inc
Pulmocide Ltd
Scynexis Inc
Sealife PHARMA GMBH
Shaanxi Synthetic Pharmaceutical Co Ltd
TFF Pharmaceuticals Inc
Trilogy Therapeutics Inc
Visterra Inc
Aspergillosis – Drug Profiles
Aspergillosis – Dormant Projects
Aspergillosis – Discontinued Products
Aspergillosis – Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Aspergillosis, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Aspergillosis - Pipeline by ABIONYX Pharma SA, H2 2019
Aspergillosis - Pipeline by Acea Biotech Inc, H2 2019
Aspergillosis - Pipeline by Amplyx Pharmaceuticals Inc, H2 2019
Aspergillosis - Pipeline by Argenx SE, H2 2019
Aspergillosis - Pipeline by Basilea Pharmaceutica Ltd, H2 2019
Aspergillosis - Pipeline by Bio-Synectics Inc, H2 2019
Aspergillosis - Pipeline by Biosergen AS, H2 2019
Aspergillosis - Pipeline by Cidara Therapeutics Inc, H2 2019
Aspergillosis - Pipeline by F2G Ltd, H2 2019
Aspergillosis - Pipeline by Galephar Pharmaceutical Research Inc, H2 2019
Aspergillosis - Pipeline by iCo Therapeutics Inc, H2 2019
Aspergillosis - Pipeline by Jiangsu Aosaikang Pharmaceutical Co Ltd, H2 2019
Aspergillosis - Pipeline by Matinas BioPharma Holdings Inc, H2 2019
Aspergillosis - Pipeline by Merck & Co Inc, H2 2019
Aspergillosis - Pipeline by Molecular Express Inc, H2 2019
Aspergillosis - Pipeline by Mycovia Pharmaceuticals Inc, H2 2019
Aspergillosis - Pipeline by Nanomerics Ltd, H2 2019
Aspergillosis - Pipeline by Novabiotics Ltd, H2 2019
Aspergillosis - Pipeline by Pulmatrix Inc, H2 2019
Aspergillosis - Pipeline by Pulmocide Ltd, H2 2019
Aspergillosis - Pipeline by Scynexis Inc, H2 2019
Aspergillosis - Pipeline by Sealife PHARMA GMBH, H2 2019
Aspergillosis - Pipeline by Shaanxi Synthetic Pharmaceutical Co Ltd, H2 2019
Aspergillosis - Pipeline by TFF Pharmaceuticals Inc, H2 2019
Aspergillosis - Pipeline by Trilogy Therapeutics Inc, H2 2019
Aspergillosis - Pipeline by Visterra Inc, H2 2019
Aspergillosis - Dormant Projects, H2 2019
Aspergillosis - Dormant Projects, H2 2019 (Contd..1), H2 2019
Aspergillosis - Discontinued Products, H2 2019

【掲載企業】

ABIONYX Pharma SA
Acea Biotech Inc
Amplyx Pharmaceuticals Inc
Argenx SE
Basilea Pharmaceutica Ltd
Bio-Synectics Inc
Biosergen AS
Cidara Therapeutics Inc
F2G Ltd
Galephar Pharmaceutical Research Inc
iCo Therapeutics Inc
Jiangsu Aosaikang Pharmaceutical Co Ltd
Matinas BioPharma Holdings Inc
Merck & Co Inc
Molecular Express Inc
Mycovia Pharmaceuticals Inc
Nanomerics Ltd
Novabiotics Ltd
Pulmatrix Inc
Pulmocide Ltd
Scynexis Inc
Sealife PHARMA GMBH
Shaanxi Synthetic Pharmaceutical Co Ltd
TFF Pharmaceuticals Inc
Trilogy Therapeutics Inc
Visterra Inc

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[アスペルギルス症治療薬市場:パイプラインレビュー(2019年下半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆